Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Profound Medical ( (TSE:PRN) ).
Profound Medical’s TULSA-PRO platform and its incision-free, MRI-guided TULSA Procedure for treating prostate cancer and benign prostatic hyperplasia will be prominently featured at the 2026 Society of Interventional Radiology Annual Scientific Meeting in Toronto. Multiple oral presentations and a categorical course will showcase clinical outcomes, automated prostate segmentation, and early results from the randomized CAPTAIN trial comparing TULSA with robotic prostatectomy, underscoring growing physician awareness and the procedure’s potential to become a mainstream treatment option for men with prostate disease.
The company’s strong presence at this major specialty meeting highlights its strategy to position TULSA-PRO at the forefront of emerging interventional MRI therapies. By leveraging real-world experience and Level 1 post-market data, Profound is aiming to solidify its role in transforming prostate care, which could enhance its competitive standing in minimally invasive oncology and support broader adoption of its technology across the prostate disease spectrum.
The most recent analyst rating on (TSE:PRN) stock is a Hold with a C$8.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on PRN Stock
According to Spark, TipRanks’ AI Analyst, PRN is a Neutral.
The score is held down primarily by weak financial performance (large losses and significant cash burn) and bearish technicals (downtrend across key moving averages with negative momentum). The earnings call adds support via credible growth/profitability targets, reimbursement and pipeline tailwinds, while valuation remains constrained by ongoing losses and no stated dividend.
To see Spark’s full report on PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company specializing in AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. Its flagship TULSA-PRO platform focuses on interventional MRI procedures for prostate disease, aiming to improve clinical confidence, procedural control, and patient outcomes while minimizing side effects versus surgery or radiation.
Average Trading Volume: 20,346
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$323M
For detailed information about PRN stock, go to TipRanks’ Stock Analysis page.